NCT03127111
Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer
Not Yet Recruiting · Not specified · Renmin Hospital of Wuhan University · registry updated 2022-03-15
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The goal of this laboratory research is to look for genetic and epigenetic markers that can predict which patients with stage III colorectal cancer will benefit from fluorouracil-based adjuvant chemotherapy.
Inclusion
- Requirements for tumor parameters
- Histologically confirmed colorectal adenocarcinoma.
- Stage III disease (any pT, N1-2, M0).
- Tumors must have been curatively resected (R0).
- No evidence of residual involved lymph node disease or metastatic disease at the time of registration.
- Requirements for patient characteristics
Exclusion
- Patients with a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to fluorouracil.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection-requiring intravenous antibiotics, or psychological, familial, sociological, or geographical condition that would limit compliance with study requirements
- Following cardiovascular conditions within the past 6 months: Myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia, cerebrovascular accident or transient ischemic attack, deep vein thrombosis, other significant thromboembolic event.
- Known human immunodeficiency virus (HIV)-positive patients and those with known hepatitis B or C.
- Patients with evidence of other primary malignancies within the past 5 years, excluding adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- Pregnant or nursing.